Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide
Chang-Jer Wu, Jia-Tsrong Jan, Chi-Min Chen, Hsing-Pang Hsieh, Der-Ren Hwang, Hwan-Wun Liu, Chiu-Yi Liu, Hui-Wen Huang, Su-Chin Chen, Cheng-Fong Hong, Ren-Kuo Lin, Yu-Sheng Chao, John T A Hsu, Chang-Jer Wu, Jia-Tsrong Jan, Chi-Min Chen, Hsing-Pang Hsieh, Der-Ren Hwang, Hwan-Wun Liu, Chiu-Yi Liu, Hui-Wen Huang, Su-Chin Chen, Cheng-Fong Hong, Ren-Kuo Lin, Yu-Sheng Chao, John T A Hsu
Abstract
Antiviral agents are urgently needed to fight severe acute respiratory syndrome (SARS). We showed that niclosamide, an existing antihelminthic drug, was able to inhibit replication of a newly discovered coronavirus, SARS-CoV; viral antigen synthesis was totally abolished at a niclosamide concentration of 1.56 microM, as revealed by immunoblot analysis. Thus, niclosamide represents a promising drug candidate for the effective treatment of SARS-CoV infection.
Figures
![FIG. 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/434198/bin/zac0070441190001.jpg)
![FIG. 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/434198/bin/zac0070441190002.jpg)
![FIG. 3.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/434198/bin/zac0070441190003.jpg)
Source: PubMed